Cathie Wood’s ARK Buys NVIDIA and TERADYNE, Sells META and ROCKET LAB

Cathie Wood’s ARK ETFs have reported their daily trades for Tuesday, July 22nd, 2025, with significant activity across several sectors. Leading the purchases, ARK’s ARKK ETF invested heavily in Teradyne Inc (NYSE:NASDAQ:TER), buying 85,030 shares with a total dollar value of $8,062,544. This move marks a continued bullish stance on the semiconductor testing company, as ARK has been accumulating shares over the past week.

In another major buy, ARK’s ARKX (NYSE:ARKX) ETF added 10,307 shares of NVIDIA Corp (NASDAQ:NVDA), a leading graphics processor manufacturer, totaling $1,766,413. This trade follows a pattern of consistent investment in NVIDIA, signaling ARK’s confidence in the company’s growth prospects.

ARKX ETF also expanded its holdings in Advanced Micro Devices Inc (NASDAQ:AMD) and L3Harris Technologies Inc (NYSE:LHX), purchasing 4,980 and 2,997 shares worth $781,860 and $788,480, respectively. These acquisitions showcase ARK’s strategy of investing in innovative and technologically advanced companies.

On the sell side, ARK’s ARKK ETF divested from Meta Platforms Inc (NASDAQ:META), offloading 3,502 shares at a value of $2,496,820. This sale indicates a possible shift in ARK’s assessment of the social media giant’s future performance.

Additionally, ARK’s ARKX ETF sold a significant stake in Rocket Lab USA Inc (NASDAQ:RKLB), parting with 64,326 shares for a total of $3,035,543. This trade comes amidst a broader trend of ARK reducing its position in the aerospace manufacturer.

Other trades included the sale of shares in Adaptive Biotechnologies Corp (NASDAQ:ADPT) and Guardant Health Inc (NASDAQ:GH) by ARK’s ARKG ETF, totaling $55,972 and $611,712, respectively. These sales reflect ongoing adjustments to ARK’s health technology and genomics-focused portfolio.

Investors following ARK’s moves will note the fund’s continued investment in Caris Life Sciences Inc (Private:CAI), with an additional 14,708 shares acquired, valued at $416,089. This follows a series of purchases in the company over the previous days, highlighting ARK’s growing interest in the personalized medicine space.

Overall, ARK’s latest trades underscore a strategic focus on companies poised for growth in technology and genomics, while adjusting holdings in other sectors to optimize portfolio performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.